Table 3.

Incidence of non-Hodgkin lymphoma by duration of cholesterol-lowering drug use, follow-up year, and subtype, Cancer Prevention Study II Nutrition Cohort, 1997—2007a

No reported useFormer useCurrent use, <5 yCurrent use, ≥5 y
NHL subtypeCasesRR (95% CI)CasesRR (95% CI)CasesRR (95% CI)CasesRR (95% CI)
Diffuse large B-cell lymphoma2201.00 (ref)120.76 (0.42–1.39)510.89 (0.64–1.23)420.68 (0.46–1.00)
SLL/CLLb2121.00 (ref)151.01 (0.59–1.74)500.91 (0.66–1.27)490.85 (0.58–1.23)
Multiple myeloma1591.00 (ref)60.49 (0.21–1.12)441.00 (0.70–1.43)360.72 (0.47–1.11)
Follicular lymphoma1331.00 (ref)101.09 (0.56–2.13)310.94 (0.62–1.44)351.05 (0.67–1.64)
Marginal zone lymphoma611.00 (ref)40.78 (0.27–2.21)140.84 (0.45–1.58)70.36 (0.15–0.86)
T-cell NHL471.00 (ref)20.54 (0.13–2.28)110.85 (0.42–1.72)120.80 (0.37–1.73)
Other or unknown subtype1731.00 (ref)100.79 (0.41–1.53)240.49 (0.31–0.77)340.65 (0.42–1.01)
  • aAdjusted for age, sex, race, education, smoking, BMI, physical activity level, NSAID use, hormone therapy, history of elevated cholesterol, heart disease, diabetes, and hypertension.

  • bSmall lymphocytic leukemia or chronic lymphocytic leukemia.